Study Population
Between November 27, 2017, and January 28, 2021, 175 patients were enrolled in the study: 111 across all single-agent cohorts and 64 in the giredestrant 100 mg combination cohort with palbociclib. Of 175 patients enrolled, 171 were evaluable for pharmacokinetics. In the single-agent dose-escalation phase, there were 29 patients with calculated pharmacokinetic parameters (including 21 with a 7-day single-dose pharmacokinetic lead-in). The data cut-off date was September 17, 2021.